ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, confirms that it will be announcing its Interim results for the six months ended 30 June 2017 on Wednesday 27 September 2017.
-Ends-
For further information please contact:
ImmuPharma plc (www.immupharma.org)
+ 44 (0) 20 7152 4080
Tim McCarthy, Chairman
Lisa Baderoon, Head of Investor Relations
Twitter: @immupharma
+ 44 (0) 7721 413496
Northland Capital Partners Limited (Joint Broker)
Patrick Claridge, David Hignell, Jamie Spotswood, Corporate Finance
Rob Rees, Corporate Broking
+44 (0)20 3861 6625
This information is provided by RNS
The company news service from the London Stock Exchange
